Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 243Neoplasms 17Neoplasm Metastasis 15Carcinoma, Intraductal, Noninfiltrating 11Breast Diseases 8Advanced Breast Cancer 8Breast Neoplasms, Male 7Breast Carcinoma In Situ 7Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Endometrial Neoplasms 5Arthralgia 5Neoplasms by Site 3Breast Cancer Metastatic 3Uterine Cervical Neoplasms 2Recurrence 2Patient Compliance 2Osteoporosis 2Obesity 2Multiple Endocrine Neoplasia Type 1 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasm Female 2Vitamin D Deficiency 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Seizures 1Sarcoma 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1enzalutamide 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Anastrozole × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡